Open Actively Recruiting

Mindfulness Meditation and Insomnia in Alzheimer Disease Caregivers

About

Brief Summary

Treatment of insomnia in caregivers is needed given that 60% of Alzheimer disease caregivers report sleep complaints, and insomnia may add to the burden of AD caregiving and contribute to morbidity and mortality risk. This is the first intervention trial in AD caregivers to target insomnia and also evaluate two mechanisms of chronic disease risk, inflammation and cellular aging

Primary Purpose
Treatment
Study Type
Interventional
Phase
N/A

Eligibility

Gender
All
Healthy Volunteers
No
Minimum Age
45 Years
Maximum Age
95 Years

Inclusion Criteria:

  • Alzheimer or other dementia caregivers
  • Older than 45 years of age
  • Self-identified as the principal person taking care of the patient with Alzheimer or other dementia
  • Diagnostic and Statistical Manual Criteria - 5 for Insomnia

Exclusion Criteria:

  • Psychiatric disorders including current major depressive disorder or other current DSM-5 psychiatric disorder (e.g. substance dependence) with the exception of anxiety disorder;
  • Psychotic symptoms;
  • Acute suicidal or violent behavior or history of suicide attempt within the last year
  • Other sleep disorders including current or lifetime history of sleep apnea, nocturnal myoclonus, phase-shift disorder as identified by SCID-5 and Duke Structured Interview for Sleep Disorders (DSISD)
  • Medical conditions such as acute or uncontrolled medical illness (e.g., major surgery, metastatic cancer, Class III heart failure, inflammatory disorder)
  • Chronic infections
  • Obesity with body mass index (BMI) >35
  • Use of hormone containing medications including steroids or immune modifying drugs
  • Daily use of analgesics such as opioids;
  • Daily us of sedative hypnotic medications
  • Cognitive impairment as evidenced by DSM-5 interview and/or Mini-Mental Status Exam (MMSE < 26)
  • Actively practicing a mind body intervention.

Join this Trial

Contact our clinical trial navigators for opportunities that may be suitable for you
Study Stats
Protocol No.
16-001256
Category
Semel Institute (Psychiatry)
Principal Investigator
Contact
Nina Sadeghi
Location
  • UCLA Westwood
For Providers
NCT No.
NCT03538574
For detailed technical eligibility, visit ClinicalTrials.gov.